You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

INOT

Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
New Drug Funding Program
    Inotuzumab Ozogamicin - Relapsed or Refractory Acute Lymphoblastic Leukemia

You might also be interested in